116 related articles for article (PubMed ID: 32851890)
1. Investigating the Impact of OGT Inhibition on Doxorubicin- and Docetaxel-Induced Cytotoxicity in PC-3 and WPMY-1 Cells.
Makwana V; Dukie AS; Rudrawar S
Int J Toxicol; 2020; 39(6):586-593. PubMed ID: 32851890
[TBL] [Abstract][Full Text] [Related]
2. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer.
Wang L; Chen S; Zhang Z; Zhang J; Mao S; Zheng J; Xuan Y; Liu M; Cai K; Zhang W; Guo Y; Zhai W; Yao X
BMC Cancer; 2018 Nov; 18(1):1141. PubMed ID: 30453909
[TBL] [Abstract][Full Text] [Related]
3. Design of OSMI-4 Analogs Using Scaffold Hopping: Investigating the Importance of the Uridine Mimic in the Binding of OGT Inhibitors.
Balsollier C; Tomašič T; Yasini D; Bijkerk S; Anderluh M; Pieters RJ
ChemMedChem; 2023 Apr; 18(8):e202300001. PubMed ID: 36752318
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc Transferase Inhibitor Synergistically Enhances Doxorubicin-Induced Apoptosis in HepG2 Cells.
Lee SJ; Kwon OS
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33121131
[TBL] [Abstract][Full Text] [Related]
5. High OGT activity is essential for MYC-driven proliferation of prostate cancer cells.
Itkonen HM; Urbanucci A; Martin SE; Khan A; Mathelier A; Thiede B; Walker S; Mills IG
Theranostics; 2019; 9(8):2183-2197. PubMed ID: 31149037
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.
Xia M; Wang S; Qi Y; Long K; Li E; He L; Pan F; Guo Z; Hu Z
Front Oncol; 2022; 12():993243. PubMed ID: 36439421
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Eftekhari S; Montazeri H; Tarighi P
Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of O-Linked N-Acetylglucosamine Transferase Reduces Replication of Herpes Simplex Virus and Human Cytomegalovirus.
Angelova M; Ortiz-Meoz RF; Walker S; Knipe DM
J Virol; 2015 Aug; 89(16):8474-83. PubMed ID: 26041297
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
10. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
11. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
12. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.
Zhang X; Ma L; Qi J; Shan H; Yu W; Gu Y
Mol Cell Biochem; 2015 Dec; 410(1-2):101-10. PubMed ID: 26318312
[TBL] [Abstract][Full Text] [Related]
13. Silencing β-linked N-acetylglucosamine transferase induces apoptosis in human gastric cancer cells through PUMA and caspase-3 pathways.
Wen T; Hou K; Li Z; Li L; Yu H; Liu Y; Li Y; Yin Z
Oncol Rep; 2015 Dec; 34(6):3140-6. PubMed ID: 26397041
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Pinto AC; Moreira JN; Simões S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
[TBL] [Abstract][Full Text] [Related]
15. Intracellular Hydrolysis of Small-Molecule
Loi EM; Weiss M; Pajk S; Gobec M; Tomašič T; Pieters RJ; Anderluh M
Molecules; 2020 Jul; 25(15):. PubMed ID: 32722493
[No Abstract] [Full Text] [Related]
16. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism.
Itkonen HM; Gorad SS; Duveau DY; Martin SE; Barkovskaya A; Bathen TF; Moestue SA; Mills IG
Oncotarget; 2016 Mar; 7(11):12464-76. PubMed ID: 26824323
[TBL] [Abstract][Full Text] [Related]
18. Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.
Lin B; Chai S; Zhang Q; Lu Y; Hu J; Zhang J; Du YZ; Wu L
Mol Pharm; 2024 Jan; 21(1):102-112. PubMed ID: 37994899
[TBL] [Abstract][Full Text] [Related]
19. A small molecule that inhibits OGT activity in cells.
Ortiz-Meoz RF; Jiang J; Lazarus MB; Orman M; Janetzko J; Fan C; Duveau DY; Tan ZW; Thomas CJ; Walker S
ACS Chem Biol; 2015 Jun; 10(6):1392-7. PubMed ID: 25751766
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of AMANTADIG - a semisynthetic digitoxigenin derivative - alone and in combination with docetaxel in human hormone-refractory prostate cancer cells and its effect on Na
Silva IT; Munkert J; Nolte E; Schneider NFZ; Rocha SC; Ramos ACP; Kreis W; Braga FC; de Pádua RM; Taranto AG; Cortes V; Barbosa LA; Wach S; Taubert H; Simões CMO
Biomed Pharmacother; 2018 Nov; 107():464-474. PubMed ID: 30107342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
